Thank you for the reply, sorry it's taken a while for me to catch up with this.
Is it fair to assume then that patients in this trial may also be still undergoing their regular or other treatment(s) in addition to receiving Bisantrene? I'm not sure how trials work in this regard, but I would assume that by precluding them if they are undergoing other treatment that would make it much harder to recruit.
If this is the case, do you see that would complicate the ability to gather good data on dosage regarding FTO inhibition, or is it an opportunity to gather early data on the way that Bisantrene works with other treatments? Or it could be both possibly I guess.
Thank you for the reply, sorry it's taken a while for me to...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.75 |
Change
0.010(0.57%) |
Mkt cap ! $298.0M | |||
| Open | High | Low | Value | Volume |
| $1.73 | $1.83 | $1.73 | $272.0K | 152.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9998 | $1.75 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.79 | 2000 | 1 |
View Market Depth
| Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |